Patient Co-payment and Adherence to Statins: A Review and Case Studies
- First Online:
- 297 Downloads
This study aims to review the international literature about whether there is an association between co-payment and statin adherence, and to present case studies to illustrate the impact of a reduction in patient co-payment associated with generic drugs on improving therapy adherence.
Studies that examined the impact of patient co-payment on statin adherence were identified in PubMed, Cochrane Central Register of Controlled Trials and EconLit up to January 2013. A standardized data extraction form was completed for each included study, collecting information about country, sample, setting, adherence measure, design, results about the impact of co-payment on statin adherence, and methodological quality. Two cases from the outpatient clinic of one the authors (PRS) were added.
The literature supported a statistically significant negative association between co-payment and statin adherence. This association appeared to be influenced by the absolute level of co-payments, the size of the co-payment change, whether co-payment increases or decreases, the time horizon over which the impact of a co-payment change is examined, the type of drug for which co-payment changes (e.g. generic or branded drug), the availability of alternative drugs and switching behaviour. Two case studies illustrated that cost issues are important to patients and that patient adherence to statin therapy improved following a switch to generic statins.
Current studies have demonstrated that statin adherence is influenced by co-payment and a range of patient, physician and pharmacy characteristics. Nevertheless, the power of these models to explain the variation in adherence remains limited.
KeywordsAdherence Case study Co-payment Review Statin
- 4.Austvoll-Dahlgren A, Aaserud M, Vist G, Ramsay C, Oxman AD, Sturm H, et al. Pharmaceutical policies: effects of cap and co-payment on rational drug use. Cochrane Database Syst Rev. 2008:CD007017.Google Scholar
- 5.Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manage Care. 2005;11:730–40.Google Scholar
- 7.Sturm H, Austvoll-Dahlgren A, Aaserud M, Oxman AD, Ramsay C, Vernby A, et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst Rev. 2007:CD006731.Google Scholar
- 15.Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0. Cochrane Collaboration 2011. Available from: URL: www.cochrane-handbook.org.
- 16.GRADE Working Group. Grading of recommendations assessment, development and evaluation. GRADE Working Group 2013. Available from: URL: http://www.gradeworkinggroup.org/.
- 20.Schultz JS, O’Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manage Care. 2005;11:306–12.Google Scholar
- 23.Gibson TB, Mark TL, McGuigan KA, Axelsen K, Wang S. The effects of prescription drug copayments on statin adherence. Am J Manage Care. 2006;12:509–17.Google Scholar
- 24.Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manage Care. 2006;12(Spec no):SP11–9.Google Scholar
- 28.Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manage Care. 2006;12:21–8.Google Scholar
- 29.Landsman PB, Yu W, Liu X, Teutsch SM, Berger ML. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization. Am J Manage Care. 2005;11:621–8.Google Scholar
- 31.Sedjo RL, Cox ER. Lowering copayments: impact of simvastatin patent expiration on patient adherence. Am J Manage Care. 2008;14:813–8.Google Scholar
- 36.Karaca-Mandic P, Swenson T, Abraham JM, Kane RL. Association of medicare part D medication out-of-pocket costs with utilization of statin medications. Health Serv Res. 2013;48(4):1311–33.Google Scholar
- 37.Maciejewski ML, Bryson CL, Perkins M, Blough DK, Cunningham FE, Fortney JC, et al. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications. Am J Manage Care. 2010;16:e20–34.Google Scholar